Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Radium-223 in mCRPC
NCT02814669Phase 1Completed
- Sponsor
- Roche
- Start
- Sep 2016
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of atezolizumab in metastatic castration-resistant prostate cancer (mCRPC) (6 arms), sponsored by Roche. Primary endpoints: Percentage of Participants with Dose-Limiting Toxicities, Percentage of Participants with Adverse Events up to 42 months and 1 more. Started Sep 2016; status: completed.
02
Drugs
atezolizumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02814669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02814669.